Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 29, 2019 - The FDA announced the discontinuation of Novartis’ Emadine (emedastine difumarate) 0.05% ophthalmic solution.
Download PDF
Return to publications
